HYDROXYETHYL STARCH AS A PRIME FOR CARDIOPULMONARY BYPASS - EFFECTS OF 2 DIFFERENT SOLUTIONS ON HEMOSTASIS

被引:48
作者
KUITUNEN, A
HYNYNEN, M
SALMENPERA, M
HEINONEN, J
VAHTERA, E
VERKKALA, K
MYLLYLA, G
机构
[1] FINNISH RED CROSS TRANSFUS SERV,HELSINKI,FINLAND
[2] UNIV HELSINKI,DEPT THORAC & CARDIOVASC SURG,SF-00290 HELSINKI 29,FINLAND
关键词
CARDIOPULMONARY BYPASS; HEMOSTASIS; HYDROXYETHYL STARCH; PRIMING SOLUTION;
D O I
10.1111/j.1399-6576.1993.tb03783.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Hydroxyethyl starch (HES) is efficacious as a volume expander in cardiac surgical patients, but it may impair the haemostatic mechanisms. However, this latter effect may be less conspicuous with low molecular weight (LMW) solutions than with high molecular weight (HMW) solutions. Therefore, LMW- and HMW-HES solutions were evaluated as priming solutions for cardiopulmonary bypass (CPB) with respect to their effect on haemostasis. Forty-five patients undergoing coronary bypass grafting were prospectively randomised to three groups and received in a double-blind manner as their CPB prime either 20 ml . kg-1 LMW-HES (M(w) 120000), 20 ml . kg-1 HMW-HES (M(w) 400000) or Ringer's acetate 2000 ml. The final volume of the prime was completed to 2000 ml with Ringer's acetate in the HES groups. Anaesthesia and CPB management were standardised. Plasma levels of von Willebrand factor antigen and factor VIII procoagulant activity were significantly more depressed after CPB in both HES-groups as compared with the crystalloid prime group. In addition, APTT was more prolonged and the maximal amplitude of thromboelastographic tracing was more decreased in the HES-groups. It is concluded that it may be advisable to avoid HES solutions in the CPB prime, especially in patients with an increased risk for bleeding after cardiac operations.
引用
收藏
页码:652 / 658
页数:7
相关论文
共 42 条
  • [1] ANDREW SC, 1990, 12TH ANN M SOC CARD, P174
  • [2] COAGULATION, FIBRINOLYSIS AND BLEEDING AFTER OPEN-HEART-SURGERY
    BAGGE, L
    LILIENBERG, G
    NYSTROM, SO
    TYDEN, H
    [J]. SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1986, 20 (02): : 151 - 160
  • [3] AVOIDANCE OF BLOOD-TRANSFUSION IN CORONARY-ARTERY SURGERY - A TRIAL OF HYDROXYETHYL STARCH
    BELCHER, P
    LENNOX, SC
    [J]. ANNALS OF THORACIC SURGERY, 1984, 37 (05) : 365 - 370
  • [4] BIGGS R, 1976, HUMAN BLOOD COAGULAT, P657
  • [5] RETRACTED: INFLUENCE OF 5 DIFFERENT PRIMING SOLUTIONS ON PLATELET-FUNCTION IN PATIENTS UNDERGOING CARDIAC-SURGERY (Retracted article. See vol. 131, 2020)
    BOLDT, J
    ZICKMANN, B
    BALLESTEROS, BM
    STERTMANN, F
    HEMPELMANN, G
    [J]. ANESTHESIA AND ANALGESIA, 1992, 74 (02) : 219 - 225
  • [6] BULL BS, 1975, J THORAC CARDIOV SUR, V69, P685
  • [7] CARZON AA, 1967, J TRAUMA, V7, P757
  • [8] COLLUB S, 1968, SURG GYNECOL OBSTET, V127, P783
  • [9] A STUDY OF HEMOSTASIS FOLLOWING THE USE OF HIGH-DOSES OF HYDROXYETHYL STARCH 120 AND DEXTRAN IN MAJOR LAPAROTOMIES
    HALONEN, P
    LINKO, K
    MYLLYLA, G
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1987, 31 (04) : 320 - 324
  • [10] HARDISTY RM, 1962, THROMB DIATH HAEMOST, V7, P215